This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corcept (CORT) Up 15.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.
Corcept Therapeutics (CORT) Q2 Earnings Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Therapeutics (CORT) Q1 Earnings Top Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
Corcept (CORT) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.
Options Traders Expect Huge Moves in Corcept (CORT) Stock
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Corcept (CORT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Up 13.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Initiates Phase III Study for Cushing's Syndrome
by Zacks Equity Research
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.
Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -16.67% and -9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock
by Zacks Equity Research
Investors in Corcept Therapeutics (CORT) need to pay close attention to the stock based on moves in the options market lately.
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?
by Zacks Equity Research
Investors in Corcept Therapeutics (CORT) need to pay close attention to the stock based on moves in the options market lately.
Why Is Corcept Therapeutics (CORT) Up 5.3% Since Its Last Earnings Report?
by Zacks Equity Research
Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Plans Korlym Label Expansion, Pipeline in Progress
by Zacks Equity Research
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.